Poehling Capital Management’s Novartis NVS Stock Holding History

Poehling Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,745	Closed	-$391K	–	117
2020 Q1	$391K	Buy	4,745 +150	+3%	+$13.4K	0.29%	67
2019 Q4	$435K	Buy	4,595 +175	+4%	+$15.7K	0.28%	74
2019 Q3	$384K	Sell	4,420 -390	-8%	-$35K	0.28%	70
2019 Q2	$439K	Sell	4,810 -458	-9%	-$38.8K	0.29%	74
2019 Q1	$454K	Sell	5,268 -33	-0.6%	-$2.65K	0.33%	72
2018 Q4	$408K	Sell	5,301 -424	-7%	-$33K	0.39%	66
2018 Q3	$442K	Buy	5,725 +1,741	+44%	+$129K	0.31%	79
2018 Q2	$270K	Sell	3,984 -1,981	-33%	-$137K	0.24%	81
2018 Q1	$432K	Hold	5,965	–	–	0.35%	70
2017 Q4	$449K	Buy	+5,965	New	+$450K	0.38%	73

Other funds holding NVS

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Poehling Capital Management's NVS Position: Q2 2020 in Review

Poehling Capital Management sold out of Novartis (NVS) in Q2 2020, closing a stake of 4,745 shares — an estimated $391K sold.

Poehling Capital Management first reported a position in NVS in Q4 2017 and held it in 10 quarters. The position peaked at $454K in Q1 2019. 1,128 funds tracked by Wall St. Rank hold NVS as of Q2 2020.

Poehling Capital Management reported no remaining Novartis position as of Q2 2020 after selling out during the quarter.
Poehling Capital Management sold 4,745 Novartis shares in Q2 2020, an estimated $391K.
Poehling Capital Management first reported a position in Novartis in Q4 2017 and held it in 10 quarters.
Poehling Capital Management's Novartis position peaked at $454K in Q1 2019.
1,128 funds tracked by Wall St. Rank held Novartis as of Q2 2020.

Based on Poehling Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.